Telix acquires assets targeting FAP in nuclear medicine
AuntMinnie
NOVEMBER 20, 2024
Telix Pharmaceuticals is expanding its theranostic pipeline with newly acquired assets targeting fibroblast activation protein (FAP) in nuclear medicine.
AuntMinnie
NOVEMBER 20, 2024
Telix Pharmaceuticals is expanding its theranostic pipeline with newly acquired assets targeting fibroblast activation protein (FAP) in nuclear medicine.
Radiology Business
SEPTEMBER 20, 2023
Backers include societies representing radiologists and nuclear medicine professionals, device manufacturers, patient advocacy groups, and pharmaceutical companies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuntMinnie
JUNE 3, 2024
Eliot Siegel, MD; Stanislav Spiridonov, MD; Nathan Gee, MD; and Anthony Chang, PhD, are among a niche gathering of early adopters, entrepreneurial physicians, medical physicists, and investors with a sweet spot for nuclear medicine, diagnostic radiology, and radiation oncology.
AuntMinnie
JULY 12, 2024
As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. A shortage of nuclear medicine technologists means a theranostics center may need to limit its patient volume.
AuntMinnie
JANUARY 2, 2025
Telix Pharmaceuticals and the Brussels-based Oncidium foundation are highlighting results from the NOBLE Registry of TLX599-CDx (technetium-99m [Tc-99m] inhibitor of prostate-specific membrane antigen [iPSMA]), published in the European Journal of Nuclear Medicine and Molecular Imaging Reports.
AuntMinnie
JUNE 10, 2024
Evans, PhD, has been named the 2024 recipient of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Sam Gambhir Trailblazer Award. He has also co-founded, consulted, and/or served on the scientific advisory board of several biotech companies, including Oric Pharmaceuticals, Enlaza Therapeutics, and HoneyBear Biosciences.
Imaging Technology
JUNE 19, 2023
Scholz continued, “On behalf of the entire Company, we want to express our sincere appreciation to Steve Merrick, who, in his seven years of commitment and strategic leadership, has advanced NorthStar’s innovation and radiopharmaceutical expertise to the forefront of nuclear medicine. Frank Scholz, Ph.D., He holds a Ph.D.
Let's personalize your content